Nevus of Ota

Skin Disorder MONDO:0016984 Pathograph 11 Melanocytic Nevus Ophthalmic Disorder

Nevus of Ota is an oculodermal melanocytosis with usually unilateral brown or blue-gray pigmentation of facial skin, mucosae, episclera or sclera, and uvea in trigeminal nerve distributions. Falcon research emphasized a neural crest-derived melanocyte mosaicism model, ophthalmic surveillance for glaucoma and uveal melanoma, and pigment-directed laser therapy for cosmetic treatment.

Ask OpenScientist

Ask a research question about Nevus of Ota. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

5
Pathophys.
4
Phenotypes
11
Pathograph
2
Genes
1
Treatments
1
Deep Research
⚙

Pathophysiology

5
Aberrant Neural Crest Melanoblast Migration
Altered migration or persistence of neural crest-derived melanoblasts during embryogenesis is modeled as an upstream developmental event that places melanocyte precursors in facial dermis and ocular tissues along trigeminal distributions.
neural crest cell link
neural crest cell migration link ⚠ ABNORMAL
Downstream
Mosaic GNAQ-GNA11 Melanocyte Signaling
Dermal and Ocular Melanocyte Accumulation
Show evidence (1 reference)
PMID:35851619 PARTIAL Human Clinical
"ODM is a rare, prevalently unilateral, congenital condition that presents with brown or blue/gray flat asymptomatic lesions of the skin, mucosae, episclera/sclera, and uvea localized within the territory of distribution of the ophthalmic and mandibular branches of the trigeminal nerve."
The congenital, unilateral, trigeminal-territory distribution supports a developmental melanoblast migration or persistence model, although the cached abstract does not directly name neural crest migration.
Mosaic GNAQ-GNA11 Melanocyte Signaling
Postzygotic activating mutations in GNAQ or GNA11 can drive extensive dermal melanocytosis through mosaic activation of heterotrimeric G-protein signaling and MAPK-family pathways in melanocyte lineages.
melanocyte link
GNAQ link GNA11 link
G protein-coupled receptor signaling pathway link ↑ INCREASED MAPK cascade link ↑ INCREASED
Downstream
Dermal and Ocular Melanocyte Accumulation Mosaic GNAQ/GNA11 signaling increases melanocyte burden in affected pigmentary tissues.
Show evidence (3 references)
PMID:26778290 SUPPORT Human Clinical
"Here, we discover that extensive dermal melanocytosis and phakomatosis pigmentovascularis are associated with activating mutations in GNA11 and GNAQ, genes that encode Gα subunits of heterotrimeric G proteins."
This supports mosaic GNAQ/GNA11 activation as a mechanistic basis for extensive dermal melanocytosis, the pigmentary process Falcon highlighted as mechanistically relevant to nevus of Ota.
PMID:26778290 SUPPORT In Vitro
"In vitro expression of mutant GNA11(R183C) and GNA11(Q209L) in human cell lines demonstrated activation of the downstream p38 MAPK signaling pathway and the p38, JNK, and ERK pathways, respectively."
This directly supports downstream MAPK-family activation from mutant GNA11 signaling.
PMID:26778290 SUPPORT Model Organism
"Transgenic mosaic zebrafish models expressing mutant GNA11(R183C) under promoter mitfa developed extensive dermal melanocytosis recapitulating the human phenotype."
This model-organism evidence supports causal sufficiency of melanocyte-lineage mutant GNA11 for dermal melanocytosis.
Dermal and Ocular Melanocyte Accumulation
Melanocytes accumulate in facial skin and ocular tissues, producing asymptomatic brown or blue-gray lesions of skin, mucosae, episclera or sclera, and uvea.
melanocyte link
pigmentation link ↑ INCREASED
skin of face link eye link iris link conjunctiva link
Downstream
Facial Blue-Gray Hyperpigmentation
Ocular Melanocytosis
Glaucoma Risk
Uveal Melanoma Risk
Show evidence (1 reference)
PMID:35851619 SUPPORT Human Clinical
"ODM is a rare, prevalently unilateral, congenital condition that presents with brown or blue/gray flat asymptomatic lesions of the skin, mucosae, episclera/sclera, and uvea localized within the territory of distribution of the ophthalmic and mandibular branches of the trigeminal nerve."
This clinical review directly supports the tissue distribution and pigmentary phenotype captured by this mechanism node.
Glaucoma Risk
Ocular melanocytosis can be complicated by glaucoma, so patients require ophthalmic assessment and ongoing surveillance.
eye link
Downstream
Glaucoma
Show evidence (2 references)
PMID:35851619 SUPPORT Human Clinical
"Glaucoma and predisposition to uveal melanoma are the main ophthalmic complications."
This supports glaucoma as a major nevus of Ota ophthalmic complication.
DOI:10.1136/bjophthalmol-2019-313984 SUPPORT Human Clinical
"Three patients developed malignant transformation to choroidal melanoma and four patients developed glaucoma."
This ocular clinical series documents glaucoma among observed complications.
Uveal Melanoma Risk
Ocular or oculodermal melanocytosis increases the risk of uveal melanoma in the affected eye, with tumor development localizing to melanocytotic tissue in reported series.
melanocyte link
iris link
Downstream
Uveal Melanoma
Show evidence (2 references)
PMID:6677847 SUPPORT Human Clinical
"The melanoma in each of these patients developed in the eye affected with ocular or oculodermal melanocytosis and not in the unaffected eye."
This supports localization of uveal melanoma to the melanocytosis-affected eye.
PMID:6677847 SUPPORT Human Clinical
"A comparison of the prevalence of ocular or oculodermal melanocytosis in patients with uveal melanoma with the prevalence of ocular or oculodermal melanocytosis in the general population, implies that there is an increased incidence of uveal melanomas in patients with ocular or oculodermal melanocytosis."
This directly supports increased uveal melanoma incidence in ocular or oculodermal melanocytosis.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Nevus of Ota Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

4
Eye 3
Ocular Melanocytosis Abnormal choroid morphology (HP:0000610)
Show evidence (1 reference)
PMID:35851619 SUPPORT Human Clinical
"ODM is a rare, prevalently unilateral, congenital condition that presents with brown or blue/gray flat asymptomatic lesions of the skin, mucosae, episclera/sclera, and uvea localized within the territory of distribution of the ophthalmic and mandibular branches of the trigeminal nerve."
This supports ocular tissue involvement as part of the defining phenotype.
Glaucoma Glaucoma (HP:0000501)
Show evidence (2 references)
PMID:35851619 SUPPORT Human Clinical
"Glaucoma and predisposition to uveal melanoma are the main ophthalmic complications."
This review identifies glaucoma as a main complication.
DOI:10.1136/bjophthalmol-2019-313984 SUPPORT Human Clinical
"Three patients developed malignant transformation to choroidal melanoma and four patients developed glaucoma."
This clinical series documents glaucoma in four nevus of Ota patients.
Uveal Melanoma Uveal melanoma (HP:0007716)
Show evidence (1 reference)
PMID:6677847 SUPPORT Human Clinical
"Fifteen patients with ocular or oculodermal melanocytosis were found after reviewing 1210 cases of histologically proven uveal melanomas."
This case-series review supports the association between oculodermal melanocytosis and uveal melanoma.
Integument 1
Facial Blue-Gray Hyperpigmentation Hyperpigmentation of the skin (HP:0000953)
Show evidence (1 reference)
PMID:35851619 SUPPORT Human Clinical
"ODM is a rare, prevalently unilateral, congenital condition that presents with brown or blue/gray flat asymptomatic lesions of the skin, mucosae, episclera/sclera, and uvea localized within the territory of distribution of the ophthalmic and mandibular branches of the trigeminal nerve."
This supports the characteristic unilateral blue-gray skin pigmentation.
🧬

Genetic Associations

2
Postzygotic GNAQ mosaicism (Causative)
Show evidence (1 reference)
PMID:26778290 SUPPORT Human Clinical
"The mutations were detected at very low levels in affected tissues but were undetectable in the blood, indicating that these conditions are postzygotic mosaic disorders."
This supports postzygotic mosaicism as the molecular genetic pattern.
Postzygotic GNA11 mosaicism (Causative)
Show evidence (1 reference)
PMID:26778290 SUPPORT Human Clinical
"Here, we discover that extensive dermal melanocytosis and phakomatosis pigmentovascularis are associated with activating mutations in GNA11 and GNAQ, genes that encode Gα subunits of heterotrimeric G proteins."
This identifies GNA11 as a somatic mosaic driver alongside GNAQ.
💊

Treatments

1
Q-switched or picosecond laser therapy
Action: laser ablation therapy MAXO:0000453
Pigment-directed laser treatment, including Q-switched Nd:YAG and picosecond laser approaches, is used for cosmetic treatment of nevus of Ota pigmentation.
Show evidence (1 reference)
clinicaltrials:NCT04481178 SUPPORT Human Clinical
"A retrospective study on efficacy and complication of laser treatment (Q-switched Nd:YAG and picosecond laser) of nevus of Ota in Thai patients"
This ClinicalTrials.gov record supports laser treatment as an evaluated therapeutic approach for nevus of Ota.
{ }

Source YAML

click to show 
name: Nevus of Ota
creation_date: "2026-05-11T00:00:00Z"
updated_date: "2026-05-11T16:50:00Z"
category: Skin Disorder
disease_term:
  preferred_term: nevus of Ota
  term:
    id: MONDO:0016984
    label: nevus of Ota
parents:
- Melanocytic Nevus
- Ophthalmic Disorder
synonyms:
- Ota's nevus
- oculodermal melanocytosis
- oculodermal melanosis
description: >-
  Nevus of Ota is an oculodermal melanocytosis with usually unilateral brown or
  blue-gray pigmentation of facial skin, mucosae, episclera or sclera, and uvea
  in trigeminal nerve distributions. Falcon research emphasized a neural
  crest-derived melanocyte mosaicism model, ophthalmic surveillance for glaucoma
  and uveal melanoma, and pigment-directed laser therapy for cosmetic treatment.
pathophysiology:
- name: Aberrant Neural Crest Melanoblast Migration
  description: >-
    Altered migration or persistence of neural crest-derived melanoblasts during
    embryogenesis is modeled as an upstream developmental event that places
    melanocyte precursors in facial dermis and ocular tissues along trigeminal
    distributions.
  cell_types:
  - preferred_term: neural crest cell
    term:
      id: CL:0011012
      label: neural crest cell
  biological_processes:
  - preferred_term: neural crest cell migration
    term:
      id: GO:0001755
      label: neural crest cell migration
    modifier: ABNORMAL
  downstream:
  - target: Mosaic GNAQ-GNA11 Melanocyte Signaling
  - target: Dermal and Ocular Melanocyte Accumulation
  evidence:
  - reference: PMID:35851619
    reference_title: "An update on ophthalmological perspectives in oculodermal melanocytosis (Nevus of Ota)."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ODM is a rare, prevalently unilateral, congenital condition that presents
      with brown or blue/gray flat asymptomatic lesions of the skin, mucosae,
      episclera/sclera, and uvea localized within the territory of distribution
      of the ophthalmic and mandibular branches of the trigeminal nerve.
    explanation: >-
      The congenital, unilateral, trigeminal-territory distribution supports a
      developmental melanoblast migration or persistence model, although the
      cached abstract does not directly name neural crest migration.
- name: Mosaic GNAQ-GNA11 Melanocyte Signaling
  description: >-
    Postzygotic activating mutations in GNAQ or GNA11 can drive extensive dermal
    melanocytosis through mosaic activation of heterotrimeric G-protein signaling
    and MAPK-family pathways in melanocyte lineages.
  genes:
  - preferred_term: GNAQ
    term:
      id: hgnc:4390
      label: GNAQ
  - preferred_term: GNA11
    term:
      id: hgnc:4379
      label: GNA11
  cell_types:
  - preferred_term: melanocyte
    term:
      id: CL:0000148
      label: melanocyte
  biological_processes:
  - preferred_term: G protein-coupled receptor signaling pathway
    term:
      id: GO:0007186
      label: G protein-coupled receptor signaling pathway
    modifier: INCREASED
  - preferred_term: MAPK cascade
    term:
      id: GO:0000165
      label: MAPK cascade
    modifier: INCREASED
  downstream:
  - target: Dermal and Ocular Melanocyte Accumulation
    description: >-
      Mosaic GNAQ/GNA11 signaling increases melanocyte burden in affected
      pigmentary tissues.
  evidence:
  - reference: PMID:26778290
    reference_title: "Mosaic Activating Mutations in GNA11 and GNAQ Are Associated with Phakomatosis Pigmentovascularis and Extensive Dermal Melanocytosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we discover that extensive dermal melanocytosis and phakomatosis
      pigmentovascularis are associated with activating mutations in GNA11 and
      GNAQ, genes that encode Gα subunits of heterotrimeric G proteins.
    explanation: >-
      This supports mosaic GNAQ/GNA11 activation as a mechanistic basis for
      extensive dermal melanocytosis, the pigmentary process Falcon highlighted
      as mechanistically relevant to nevus of Ota.
  - reference: PMID:26778290
    reference_title: "Mosaic Activating Mutations in GNA11 and GNAQ Are Associated with Phakomatosis Pigmentovascularis and Extensive Dermal Melanocytosis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In vitro expression of mutant GNA11(R183C) and GNA11(Q209L) in human cell
      lines demonstrated activation of the downstream p38 MAPK signaling pathway
      and the p38, JNK, and ERK pathways, respectively.
    explanation: >-
      This directly supports downstream MAPK-family activation from mutant
      GNA11 signaling.
  - reference: PMID:26778290
    reference_title: "Mosaic Activating Mutations in GNA11 and GNAQ Are Associated with Phakomatosis Pigmentovascularis and Extensive Dermal Melanocytosis."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Transgenic mosaic zebrafish models expressing mutant GNA11(R183C) under
      promoter mitfa developed extensive dermal melanocytosis recapitulating the
      human phenotype.
    explanation: >-
      This model-organism evidence supports causal sufficiency of melanocyte-lineage
      mutant GNA11 for dermal melanocytosis.
- name: Dermal and Ocular Melanocyte Accumulation
  description: >-
    Melanocytes accumulate in facial skin and ocular tissues, producing
    asymptomatic brown or blue-gray lesions of skin, mucosae, episclera or
    sclera, and uvea.
  cell_types:
  - preferred_term: melanocyte
    term:
      id: CL:0000148
      label: melanocyte
  biological_processes:
  - preferred_term: pigmentation
    term:
      id: GO:0043473
      label: pigmentation
    modifier: INCREASED
  locations:
  - preferred_term: skin of face
    term:
      id: UBERON:1000021
      label: skin of face
  - preferred_term: eye
    term:
      id: UBERON:0000970
      label: eye
  - preferred_term: iris
    term:
      id: UBERON:0001769
      label: iris
  - preferred_term: conjunctiva
    term:
      id: UBERON:0001811
      label: conjunctiva
  downstream:
  - target: Facial Blue-Gray Hyperpigmentation
  - target: Ocular Melanocytosis
  - target: Glaucoma Risk
  - target: Uveal Melanoma Risk
  evidence:
  - reference: PMID:35851619
    reference_title: "An update on ophthalmological perspectives in oculodermal melanocytosis (Nevus of Ota)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ODM is a rare, prevalently unilateral, congenital condition that presents
      with brown or blue/gray flat asymptomatic lesions of the skin, mucosae,
      episclera/sclera, and uvea localized within the territory of distribution
      of the ophthalmic and mandibular branches of the trigeminal nerve.
    explanation: >-
      This clinical review directly supports the tissue distribution and
      pigmentary phenotype captured by this mechanism node.
- name: Glaucoma Risk
  description: >-
    Ocular melanocytosis can be complicated by glaucoma, so patients require
    ophthalmic assessment and ongoing surveillance.
  locations:
  - preferred_term: eye
    term:
      id: UBERON:0000970
      label: eye
  downstream:
  - target: Glaucoma
  evidence:
  - reference: PMID:35851619
    reference_title: "An update on ophthalmological perspectives in oculodermal melanocytosis (Nevus of Ota)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Glaucoma and predisposition to uveal melanoma are the main ophthalmic
      complications.
    explanation: >-
      This supports glaucoma as a major nevus of Ota ophthalmic complication.
  - reference: DOI:10.1136/bjophthalmol-2019-313984
    reference_title: "Naevus of Ota: clinical characteristics and proposal for a new ocular classification and grading system"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Three patients developed malignant transformation to choroidal melanoma
      and four patients developed glaucoma.
    explanation: >-
      This ocular clinical series documents glaucoma among observed complications.
- name: Uveal Melanoma Risk
  description: >-
    Ocular or oculodermal melanocytosis increases the risk of uveal melanoma in
    the affected eye, with tumor development localizing to melanocytotic tissue
    in reported series.
  cell_types:
  - preferred_term: melanocyte
    term:
      id: CL:0000148
      label: melanocyte
  locations:
  - preferred_term: iris
    term:
      id: UBERON:0001769
      label: iris
  downstream:
  - target: Uveal Melanoma
  evidence:
  - reference: PMID:6677847
    reference_title: Ocular and oculodermal melanocytosis associated with uveal melanoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The melanoma in each of these patients developed in the eye affected with
      ocular or oculodermal melanocytosis and not in the unaffected eye.
    explanation: >-
      This supports localization of uveal melanoma to the melanocytosis-affected
      eye.
  - reference: PMID:6677847
    reference_title: Ocular and oculodermal melanocytosis associated with uveal melanoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A comparison of the prevalence of ocular or oculodermal melanocytosis in
      patients with uveal melanoma with the prevalence of ocular or oculodermal
      melanocytosis in the general population, implies that there is an increased
      incidence of uveal melanomas in patients with ocular or oculodermal
      melanocytosis.
    explanation: >-
      This directly supports increased uveal melanoma incidence in ocular or
      oculodermal melanocytosis.
phenotypes:
- category: Dermatologic
  name: Facial Blue-Gray Hyperpigmentation
  diagnostic: true
  description: >-
    Usually unilateral brown or blue-gray flat facial pigmentation affects skin
    in trigeminal nerve distributions.
  phenotype_term:
    preferred_term: Hyperpigmentation of the skin
    term:
      id: HP:0000953
      label: Hyperpigmentation of the skin
  evidence:
  - reference: PMID:35851619
    reference_title: "An update on ophthalmological perspectives in oculodermal melanocytosis (Nevus of Ota)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ODM is a rare, prevalently unilateral, congenital condition that presents
      with brown or blue/gray flat asymptomatic lesions of the skin, mucosae,
      episclera/sclera, and uvea localized within the territory of distribution
      of the ophthalmic and mandibular branches of the trigeminal nerve.
    explanation: >-
      This supports the characteristic unilateral blue-gray skin pigmentation.
- category: Ophthalmologic
  name: Ocular Melanocytosis
  diagnostic: true
  description: >-
    Pigmentation can involve episclera or sclera and uveal structures of the
    affected eye.
  phenotype_term:
    preferred_term: Ocular melanocytosis
    term:
      id: HP:0000610
      label: Abnormal choroid morphology
  evidence:
  - reference: PMID:35851619
    reference_title: "An update on ophthalmological perspectives in oculodermal melanocytosis (Nevus of Ota)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ODM is a rare, prevalently unilateral, congenital condition that presents
      with brown or blue/gray flat asymptomatic lesions of the skin, mucosae,
      episclera/sclera, and uvea localized within the territory of distribution
      of the ophthalmic and mandibular branches of the trigeminal nerve.
    explanation: >-
      This supports ocular tissue involvement as part of the defining phenotype.
- category: Ophthalmologic
  name: Glaucoma
  description: Glaucoma is a major ophthalmic complication of nevus of Ota.
  phenotype_term:
    preferred_term: Glaucoma
    term:
      id: HP:0000501
      label: Glaucoma
  evidence:
  - reference: PMID:35851619
    reference_title: "An update on ophthalmological perspectives in oculodermal melanocytosis (Nevus of Ota)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Glaucoma and predisposition to uveal melanoma are the main ophthalmic
      complications.
    explanation: >-
      This review identifies glaucoma as a main complication.
  - reference: DOI:10.1136/bjophthalmol-2019-313984
    reference_title: "Naevus of Ota: clinical characteristics and proposal for a new ocular classification and grading system"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Three patients developed malignant transformation to choroidal melanoma
      and four patients developed glaucoma.
    explanation: >-
      This clinical series documents glaucoma in four nevus of Ota patients.
- category: Cancer
  name: Uveal Melanoma
  description: >-
    Uveal melanoma is a serious malignancy risk in ocular or oculodermal
    melanocytosis.
  phenotype_term:
    preferred_term: Uveal melanoma
    term:
      id: HP:0007716
      label: Uveal melanoma
  evidence:
  - reference: PMID:6677847
    reference_title: Ocular and oculodermal melanocytosis associated with uveal melanoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fifteen patients with ocular or oculodermal melanocytosis were found after
      reviewing 1210 cases of histologically proven uveal melanomas.
    explanation: >-
      This case-series review supports the association between oculodermal
      melanocytosis and uveal melanoma.
genetic:
- name: Postzygotic GNAQ mosaicism
  association: Causative
  gene_term:
    preferred_term: GNAQ
    term:
      id: hgnc:4390
      label: GNAQ
  variant_origin: SOMATIC
  notes: >-
    Falcon identified postzygotic GNAQ and GNA11 activation as the strongest
    molecular mechanism for extensive dermal melanocytosis and related
    oculodermal melanocytosis phenotypes, rather than a germline inheritance
    pattern for typical isolated nevus of Ota.
  evidence:
  - reference: PMID:26778290
    reference_title: "Mosaic Activating Mutations in GNA11 and GNAQ Are Associated with Phakomatosis Pigmentovascularis and Extensive Dermal Melanocytosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The mutations were detected at very low levels in affected tissues but were
      undetectable in the blood, indicating that these conditions are postzygotic
      mosaic disorders.
    explanation: >-
      This supports postzygotic mosaicism as the molecular genetic pattern.
- name: Postzygotic GNA11 mosaicism
  association: Causative
  gene_term:
    preferred_term: GNA11
    term:
      id: hgnc:4379
      label: GNA11
  variant_origin: SOMATIC
  notes: >-
    GNA11 is a co-equal somatic mosaic driver in extensive dermal
    melanocytosis and related oculodermal melanocytosis phenotypes.
  evidence:
  - reference: PMID:26778290
    reference_title: "Mosaic Activating Mutations in GNA11 and GNAQ Are Associated with Phakomatosis Pigmentovascularis and Extensive Dermal Melanocytosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we discover that extensive dermal melanocytosis and phakomatosis
      pigmentovascularis are associated with activating mutations in GNA11 and
      GNAQ, genes that encode Gα subunits of heterotrimeric G proteins.
    explanation: >-
      This identifies GNA11 as a somatic mosaic driver alongside GNAQ.
progression:
- phase: Congenital or early-life onset
  age_range: Birth to childhood
  evidence:
  - reference: PMID:35851619
    reference_title: "An update on ophthalmological perspectives in oculodermal melanocytosis (Nevus of Ota)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ODM is a rare, prevalently unilateral, congenital condition that presents
      with brown or blue/gray flat asymptomatic lesions of the skin, mucosae,
      episclera/sclera, and uvea localized within the territory of distribution
      of the ophthalmic and mandibular branches of the trigeminal nerve.
    explanation: >-
      This supports congenital onset as the typical temporal pattern.
diagnosis:
- name: Comprehensive ophthalmological examination and multimodal imaging
  description: >-
    Diagnosis is primarily clinical, but comprehensive ophthalmologic evaluation
    and imaging are important because pigmentation can obscure retinal and
    choroidal findings and because glaucoma or melanoma can involve anterior and
    posterior ocular structures.
  evidence:
  - reference: PMID:35851619
    reference_title: "An update on ophthalmological perspectives in oculodermal melanocytosis (Nevus of Ota)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diagnosis and management are through comprehensive opthalmological
      examination and traditional imaging methods such as ultrasonography and
      fluorescein/indocyanine green angiography as pigmentation of the fundus can
      conceal subtle retinal and choroidal alterations.
    explanation: >-
      This supports comprehensive ophthalmologic examination and imaging in
      diagnosis and management.
treatments:
- name: Q-switched or picosecond laser therapy
  description: >-
    Pigment-directed laser treatment, including Q-switched Nd:YAG and picosecond
    laser approaches, is used for cosmetic treatment of nevus of Ota pigmentation.
  treatment_term:
    preferred_term: laser ablation therapy
    term:
      id: MAXO:0000453
      label: laser ablation therapy
  evidence:
  - reference: clinicaltrials:NCT04481178
    reference_title: A Retrospective Study on Laser Treatment of Nevus of Ota in Thai Patients
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A retrospective study on efficacy and complication of laser treatment
      (Q-switched Nd:YAG and picosecond laser) of nevus of Ota in Thai patients
    explanation: >-
      This ClinicalTrials.gov record supports laser treatment as an evaluated
      therapeutic approach for nevus of Ota.
notes: >-
  Falcon found no strong evidence for routine germline testing, infectious
  etiology, environmental causation, or established primary prevention for
  typical isolated nevus of Ota.
📚

References & Deep Research

Deep Research

1
Falcon ▸
1. Disease Information
Edison Scientific Literature 32 citations 2026-05-11T12:47:59.381060

1. Disease Information

1.1 Overview (definition; current understanding)

Nevus of Ota is described as a benign dermal melanocytic lesion with typical unilateral blue-gray macules/patches along the ophthalmic (V1) and maxillary (V2) trigeminal distributions, frequently with ocular involvement. (williams2021melanomainthe pages 1-2)

An ophthalmology-focused review defines oculodermal melanocytosis (ODM; Nevus of Ota) as a “rare, prevalently unilateral, congenital condition” presenting with “brown or blue/gray flat asymptomatic lesions of the skin, mucosae, episclera/sclera, and uvea” in trigeminal territory. (abdolrahimzadeh2023anupdateon pages 1-3)

1.2 Key identifiers (ontology and coding)

  • MeSH descriptor: Nevus of Ota (MeSH ID D009507) is explicitly present in a ClinicalTrials.gov record for laser treatment outcomes (NCT04481178). (NCT04481178 chunk 1)
  • ICD-10/ICD-11, OMIM, Orphanet, MONDO: Not present in the retrieved full texts in this tool run; therefore these identifiers cannot be confirmed from the provided evidence corpus. (NCT04481178 chunk 1)

1.3 Common synonyms / alternative names

  • Oculodermal melanocytosis / oculodermal melanosis (vishnevskiadai2021naevusofota pages 1-2, zheng2024resultsandfollowup pages 1-2)
  • Nevus fuscoceruleus ophthalmomaxillaris (williams2021melanomainthe pages 1-2, vishnevskiadai2021naevusofota pages 1-2)

1.4 Evidence source type

The information in this report is derived from a mixture of aggregated disease-level reviews and case-series/cohort clinical studies (e.g., multimodal imaging review; retrospective ocular case series; infant laser cohort), plus case-based molecular reports relevant to genetic mechanisms and malignant transformation. (vishnevskiadai2021naevusofota pages 1-1, abdolrahimzadeh2023anupdateon pages 1-3, zheng2024resultsandfollowup pages 1-2, toomey2019gnaqandpms1 pages 1-2)

2. Etiology

2.1 Disease causal factors (mechanistic/developmental)

Multiple sources frame Nevus of Ota/ODM as a neural crest developmental melanocytosis. The 2023 ophthalmology review links etiopathogenesis to altered migration of neural crest melanoblasts in embryogenesis. (abdolrahimzadeh2023anupdateon pages 1-3)

2.2 Risk factors

  • Sex: Marked female predominance is repeatedly reported; the ODM review states women are “five times more afflicted.” (abdolrahimzadeh2023anupdateon pages 1-3)
  • Ethnicity/skin phototype: Higher incidence in Asians is reported (e.g., incidence 1–2 per 1000). (abdolrahimzadeh2023anupdateon pages 1-3)

2.3 Protective factors

No protective genetic or environmental factors were identified in the retrieved texts. (abdolrahimzadeh2023anupdateon pages 1-3)

2.4 Gene–environment interactions

Direct gene–environment interaction evidence was not retrieved. However, UV exposure is discussed as a clinical factor potentially affecting recurrence after laser treatment in infants (sun exposure associated with recurrence/worsening). (zheng2024resultsandfollowup pages 1-2)

3. Phenotypes

3.1 Core phenotypes and clinical characteristics

Cutaneous phenotype (blue/gray/brown macules/patches) * Type: Clinical sign (pigmentary macules/patches). * Typical distribution: V1/V2 trigeminal territory; often unilateral. (williams2021melanomainthe pages 1-2, abdolrahimzadeh2023anupdateon pages 1-3) * Laterality frequency: “ODM occurs in just one eye in 90% of cases” in the 2023 review. (abdolrahimzadeh2023anupdateon pages 1-3)

Ocular tissue melanocytosis (episclera/sclera/uvea) and related findings * Type: Clinical sign; ocular structural pigmentation. * Frequency of ocular tissue involvement: Review reports “additional involvement of ocular tissues … in 66%” and periocular skin alone in about one-third. (abdolrahimzadeh2023anupdateon pages 1-3)

Oral mucosal involvement (rare) A 2023 review/case report on intraoral involvement notes that oral cavity involvement is uncommon and summarizes reported cases. (sharma2023intraoralnevusof pages 3-4)

3.2 Quality-of-life impact

The infant laser cohort motivates early treatment partly by psychosocial impact; the trial record similarly notes that marked facial hyperpigmentation can cause “psychosocial disturbances” prompting treatment seeking. (NCT04481178 chunk 1, zheng2024resultsandfollowup pages 1-2)

3.3 Suggested HPO terms (examples)

  • Facial hyperpigmentation (HP:0001000)
  • Blue-gray skin discoloration (phenotypic descriptor; may be mapped via “abnormality of skin pigmentation” HP:0000951)
  • Scleral hyperpigmentation (map under “abnormality of the sclera” HP:0000592; pigmentation-specific child term may be needed)
  • Ocular melanocytosis (conceptual; may map to “abnormality of the uvea” HP:0000610 plus pigmentation descriptors)
  • Glaucoma (HP:0000501)

(These term suggestions are ontology mappings; specific HPO IDs for “ocular melanocytosis” may require ontology lookup beyond the retrieved texts.)

4. Genetic/Molecular Information

4.1 Causal genes / key molecular drivers (somatic mosaicism)

Evidence supports postzygotic (somatic mosaic) activating mutations in GNAQ and GNA11 in extensive dermal melanocytosis/related phenotypes. In phakomatosis pigmentovascularis with extensive dermal melanocytosis, missense GNA11/GNAQ mutations were detected in affected skin at very low levels and were undetectable in blood, consistent with mosaicism. (thomas2016mosaicactivatingmutations pages 2-3)

A 2016 JID study provides functional support: mutant GNA11 variants activate MAPK-family pathways (p38/JNK/ERK depending on variant) and a mosaic zebrafish model recapitulated dermal melanocytosis. (thomas2016mosaicactivatingmutations pages 1-2, thomas2016mosaicactivatingmutations pages 3-5)

A 2024 review further explains that codon 209 mutations impair GTP hydrolysis and lock Gα in the active GTP-bound state, driving constitutive signaling through MAPK/ERK, Hippo/YAP-TAZ, and PI3K/AKT pathways, and notes postzygotic somatic mutations at residue 183 in GNAQ/GNA11 in relevant syndromic melanocytoses. (pilch2024gnaqgna11relatedbenignand pages 6-7)

4.2 Pathogenic variants and somatic vs germline

  • Recurrent activating hotspots: GNAQ p.R183Q and GNA11 p.R183C/p.R183S, and Q209 substitutions (e.g., Q209L/Q209P) are repeatedly implicated in mosaic melanocytosis and melanoma-related entities. (thomas2016mosaicactivatingmutations pages 3-5, pilch2024gnaqgna11relatedbenignand pages 6-7)
  • Somatic origin: low mutant allele fractions in affected tissue and absence in blood support postzygotic mosaicism. (thomas2016mosaicactivatingmutations pages 3-5, thomas2016mosaicactivatingmutations pages 2-3)

4.3 Malignant transformation genetics / modifiers (tumor progression context)

Case-based literature links uveal melanoma in the context of nevus of Ota/ocular melanosis to canonical uveal melanoma drivers and progression genes. * A 2019 report in a patient with congenital bilateral nevus of Ota and uveal melanoma identified GNAQ R183Q and a truncating mutation in mismatch repair gene PMS1 in tumor sequencing. (toomey2019gnaqandpms1 pages 1-2) * A melanoma-focused review for dermatologists reports: “Approximately 6% of lesions harbor mutations in GNAQ.” (williams2021melanomainthe pages 1-2) * A case-based excerpt reports co-occurrence of BAP1 and GNAQ mutations in intracranial melanoma associated with nevus of Ota and emphasizes BAP1 immunohistochemistry for prognostication in uveal melanoma. (konstantinov2018nevusofota pages 3-3)

4.4 Suggested GO biological process terms (examples)

  • MAPK cascade (GO:0000165)
  • ERK1/ERK2 cascade (GO:0070371)
  • Neural crest cell migration (GO:0001755)
  • Melanocyte differentiation (GO:0030318)

4.5 Suggested Cell Ontology (CL) terms (examples)

  • Melanocyte (CL:0000148)
  • Neural crest cell (CL:0000135)

5. Environmental Information

Environmental/lifestyle contributors are not established as causal in the retrieved primary evidence. However, clinical observations include pigment variability with hormonal states (adolescence/pregnancy) in the ODM review, and sun exposure as a factor associated with recurrence/worsening post-laser in infants. (abdolrahimzadeh2023anupdateon pages 1-3, zheng2024resultsandfollowup pages 1-2)

No infectious etiologies were identified. (abdolrahimzadeh2023anupdateon pages 1-3)

6. Mechanism / Pathophysiology

6.1 Causal chain (current mechanistic model)

  1. Postzygotic activating mutation in GNAQ/GNA11 occurs in a progenitor lineage (mosaicism), leading to a patchy tissue distribution. (thomas2016mosaicactivatingmutations pages 2-3)
  2. Constitutively active Gαq/11 signaling leads to downstream activation of pathways including MAPK-family signaling; functional assays show mutant GNA11 activates MAPK components (p38/JNK/ERK) in cell lines, and in vivo models show increased melanocytes in epidermis/dermis. (thomas2016mosaicactivatingmutations pages 1-2, thomas2016mosaicactivatingmutations pages 3-5)
  3. Accumulation of dermal (and ocular) melanocytes produces the clinical blue/gray pigmentation phenotype. (vishnevskiadai2021naevusofota pages 1-2, abdolrahimzadeh2023anupdateon pages 1-3)
  4. In ocular tissues, melanocytosis can predispose to glaucoma and to development of uveal melanoma, necessitating ongoing ophthalmic surveillance. (abdolrahimzadeh2023anupdateon pages 1-3)

6.2 Immune involvement

No disease-specific immune mechanism evidence was retrieved. (abdolrahimzadeh2023anupdateon pages 1-3)

6.3 Suggested CL/GO/UBERON terms for mechanism mapping

  • UBERON: skin of face (UBERON:0003920), sclera (UBERON:0000974), uvea (UBERON:0001769)
  • GO (cellular component): plasma membrane (GO:0005886) (for GPCR signaling nodes), cytosol (GO:0005829)

7. Anatomical Structures Affected

7.1 Organ and tissue level

  • Skin (facial/periocular): pigmentary macules/patches in trigeminal distributions. (williams2021melanomainthe pages 1-2, abdolrahimzadeh2023anupdateon pages 1-3)
  • Eye: episclera/sclera and uvea; ocular involvement may include iris changes and other globe structures in clinical series. (vishnevskiadai2021naevusofota pages 1-2, abdolrahimzadeh2023anupdateon pages 1-3)

7.2 Localization and laterality

Typically unilateral; review reports “one eye in 90% of cases,” though bilateral cases occur. (abdolrahimzadeh2023anupdateon pages 1-3, vishnevskiadai2021naevusofota pages 1-1)

8. Temporal Development

8.1 Onset

Onset is commonly congenital or early life. The clinical trial record notes “About 50-60% of all cases have the age of onset at birth or within the first year of life, others appear before puberty.” (NCT04481178 chunk 1)

8.2 Progression / course

ODM does not tend to regress spontaneously; pigmentation may vary over time and with hormonal state. (abdolrahimzadeh2023anupdateon pages 1-3)

9. Inheritance and Population

9.1 Epidemiology (key quantitative data)

  • Asian incidence reported as 1–2 per 1000. (abdolrahimzadeh2023anupdateon pages 1-3)
  • Japanese dermatology clinic prevalence cited as ~0.4–0.8%. (williams2021melanomainthe pages 1-2)
  • Laterality: ~90% unilateral ocular involvement. (abdolrahimzadeh2023anupdateon pages 1-3)
  • Sex ratio: ~5:1 female predominance. (abdolrahimzadeh2023anupdateon pages 1-3, williams2021melanomainthe pages 1-2)

9.2 Inheritance pattern

The ODM review characterizes the condition as congenital and non-hereditary, consistent with somatic mosaicism models. (abdolrahimzadeh2023anupdateon pages 1-3)

10. Diagnostics

10.1 Clinical diagnosis

Diagnosis is primarily clinical based on characteristic distribution and ocular/skin pigmentation; ocular evaluation is emphasized due to glaucoma and melanoma risks. (abdolrahimzadeh2023anupdateon pages 1-3)

10.2 Ophthalmic evaluation and multimodal imaging (current practice trends)

The 2023 ophthalmology review provides a diagnostic/monitoring framework: * Comprehensive ophthalmologic examination plus traditional imaging (ultrasonography; fluorescein/indocyanine green angiography), because fundus pigmentation may conceal subtle retinal/choroidal alterations. (abdolrahimzadeh2023anupdateon pages 1-3) * Anterior segment OCT and ultrasound biomicroscopy for anterior segment/ciliary body evaluation when glaucoma or anterior uveal melanoma is suspected. (abdolrahimzadeh2023anupdateon pages 1-3) * Fundus autofluorescence and RPE alterations for differentiating choroidal nevi vs melanoma; enhanced depth imaging OCT for high-resolution in vivo tumor/nevi assessment and early melanoma features (subretinal fluid, RPE abnormalities, choriocapillaris compression). (abdolrahimzadeh2023anupdateon pages 1-3)

Abstract support (direct quote): the review concludes that “Novel multimodal imaging techniques are significant in the diagnosis and management of the ophthalmic complications of ODM.” (abdolrahimzadeh2023anupdateon pages 1-3)

10.3 Histopathology

A 2023 bilateral case-series review states that nevus of Ota shows melanocytes in the dermis (and notes epidermal involvement in their phrasing). (kumari2023bilateralnevusof pages 4-5)

10.4 Genetic testing

Routine germline genetic testing is not established for typical isolated nevus of Ota in the retrieved texts; molecular findings mainly come from research sequencing of affected tissues/tumors (GNAQ/GNA11; BAP1 in associated melanomas). (toomey2019gnaqandpms1 pages 1-2, konstantinov2018nevusofota pages 3-3)

10.5 Differential diagnosis

The retrieved evidence emphasizes classification distinctions within dermal melanocytoses and diagnostic challenges; e.g., case literature distinguishes Ota nevus from acquired bilateral nevus of Ota-like macules (ABNOM) based on clinical and histopathologic patterns. (seemongaldass2025acaseof pages 5-6)

11. Outcome / Prognosis

11.1 Major complications and prognosis-relevant risks

  • Glaucoma and predisposition to uveal melanoma are highlighted as the main ophthalmic complications in ODM. (abdolrahimzadeh2023anupdateon pages 1-3)
  • The 2023 ophthalmology review states that “uveal melanoma in ODM carries twice the risk of metastasis compared to uveal melanoma in eyes without ODM,” underscoring prognostic importance of early detection. (abdolrahimzadeh2023anupdateon pages 1-3)
  • In a 40-patient ocular series, 4 developed glaucoma and 3 developed malignant transformation to choroidal melanoma. (vishnevskiadai2021naevusofota pages 1-1)

11.2 Prognostic factors

The retrieved texts do not provide validated prognostic models specific to nevus of Ota itself; prognostication is more developed for uveal melanoma (e.g., BAP1 loss). (konstantinov2018nevusofota pages 3-3)

12. Treatment

12.1 Standard of care / current applications

Laser therapy (selective photothermolysis) is the main real-world treatment for cosmetic pigment reduction, especially Q-switched pigment lasers (ruby 694 nm, alexandrite 755 nm, Nd:YAG 1064 nm). (kumari2023bilateralnevusof pages 4-5, NCT04481178 chunk 1)

12.2 Recent developments (prioritizing 2023–2024)

Early-life sequential Q-switched therapy (infant cohort; 2024): A large retrospective cohort of 102 infants (<1 year) treated with sequential Q-switched 755 nm (initial sessions) and 1064 nm (from session 3 onward) at 6-month intervals reports high clearance and quantifies long-term recurrence. (zheng2024resultsandfollowup pages 1-2)

Direct abstract quote: “Success rates reached 88.7% after four sessions and 99.3% after seven sessions.” (zheng2024resultsandfollowup pages 1-2)

Recurrence: among 47 infants with follow-up, 14 recurred (29.8%), and additional 2–3 sessions typically controlled recurrence. (zheng2024resultsandfollowup pages 1-2)

A table image from this study (efficacy by subtype and factors such as location/anesthesia) is available and supports the reported outcome stratification. (zheng2024resultsandfollowup media 94a4abe5, zheng2024resultsandfollowup media 9a87c0a6)

12.3 Adverse events and tolerability (quantitative)

  • In the 2024 infant cohort abstract, “No instances of serious adverse reactions, except for pain, were reported.” (zheng2024resultsandfollowup pages 1-2)
  • A Thai retrospective protocol (NCT04481178; ClinicalTrials.gov) summarizes reported complication rates from prior Q-switched laser literature: hypopigmentation 15.3%, hyperpigmentation 2.9%, texture changes 2.9%, scarring 1.9%, and cites a “success rate of 95% after 6-8 sessions.” (NCT04481178 chunk 1)

12.4 Treatment strategy / monitoring

The ophthalmology review emphasizes that monitoring for glaucoma and melanoma is central and that multimodal imaging is increasingly used to standardize complication detection and follow-up. (abdolrahimzadeh2023anupdateon pages 1-3)

12.5 MAXO term suggestions (examples)

  • Laser therapy (MAXO:0000058, “laser therapy”)
  • Ophthalmologic monitoring/surveillance (MAXO term may require lookup; concept: “medical monitoring”)

13. Prevention

Primary prevention of nevus of Ota is not described (developmental mosaic condition). Secondary/tertiary prevention focuses on preventing vision loss and melanoma morbidity through lifelong ophthalmic surveillance and early detection using multimodal imaging. (abdolrahimzadeh2023anupdateon pages 1-3)

14. Other Species / Natural Disease

A naturally occurring analogue has been described in dogs (oculodermal melanocytosis/nevus of Ota), with similar distribution and ocular involvement on histopathology, indicating cross-species relevance of neural crest–derived melanocyte disorders. (abdolrahimzadeh2023anupdateon pages 1-3)

(Note: the main veterinary primary literature was retrieved but not deeply evidence-extracted in this run; this section is therefore limited.)

15. Model Organisms

A mechanistically informative model is a mosaic transgenic zebrafish expressing mutant GNA11 (e.g., GNA11R183C) in the melanocyte lineage, which produced dermal melanocytosis, supporting causal roles for activating Gαq/11 signaling in melanocyte accumulation. (thomas2016mosaicactivatingmutations pages 1-2, thomas2016mosaicactivatingmutations pages 3-5)

Expert opinions / authoritative synthesis (from reviews)

  • The 2023 ophthalmology review highlights an expert-practice shift toward standardized use of multimodal imaging for ODM complications, stating that OCT and fundus autofluorescence have “adjunctive value” for early melanoma detection and differential diagnosis. (abdolrahimzadeh2023anupdateon pages 1-3)
  • The dermatology melanoma review stresses that while nevus of Ota is often a cosmetic concern, malignant transformation risk mandates clinician awareness and appropriate referrals. (williams2021melanomainthe pages 1-2)

Key evidence gaps in this run

  • ICD-10/ICD-11, OMIM, Orphanet, and MONDO identifiers were not available in the retrieved full texts/tools state; they require direct lookup in those external databases. (NCT04481178 chunk 1)
  • High-quality, population-based incidence/prevalence estimates outside East Asian cohorts were not retrieved here.
  • Picosecond-laser comparative effectiveness literature (2023–2024) was identified in search but some key papers were unobtainable in the current corpus, limiting systematic comparison versus Q-switched modalities.

References (URLs with publication dates where available)

  • Abdolrahimzadeh S, et al. Graefe’s Archive for Clinical and Experimental Ophthalmology. Published online 19 Jul 2022; in-issue 2023. https://doi.org/10.1007/s00417-022-05743-1 (abdolrahimzadeh2023anupdateon pages 1-3)
  • Zheng H, et al. Clinical, Cosmetic and Investigational Dermatology. Published 3 Feb 2024. https://doi.org/10.2147/CCID.S444410 (zheng2024resultsandfollowup pages 1-2)
  • Williams NM, et al. International Journal of Dermatology. 2021 (issue date Aug 2021; copyright line 2020). https://doi.org/10.1111/ijd.15135 (williams2021melanomainthe pages 1-2)
  • Thomas AC, et al. Journal of Investigative Dermatology. Apr 2016. https://doi.org/10.1016/j.jid.2015.11.027 (thomas2016mosaicactivatingmutations pages 1-2)
  • ClinicalTrials.gov. NCT04481178. First posted 22 Jul 2020. https://clinicaltrials.gov/study/NCT04481178 (NCT04481178 chunk 1)

References

  1. (abdolrahimzadeh2023anupdateon pages 1-3): Solmaz Abdolrahimzadeh, Damiano Maria Pugi, Priscilla Manni, Clemente Maria Iodice, Federico Di Tizio, Flavia Persechino, and Gianluca Scuderi. An update on ophthalmological perspectives in oculodermal melanocytosis (nevus of ota). Graefe's Archive for Clinical and Experimental Ophthalmology, 261:291-301, Jul 2023. URL: https://doi.org/10.1007/s00417-022-05743-1, doi:10.1007/s00417-022-05743-1. This article has 19 citations.

  2. (williams2021melanomainthe pages 1-2): Natalie M. Williams, Pooja Gurnani, Angelina Labib, Ronaldo Nuesi, and Keyvan Nouri. Melanoma in the setting of nevus of ota: a review for dermatologists. International Journal of Dermatology, 60:523-532, Aug 2021. URL: https://doi.org/10.1111/ijd.15135, doi:10.1111/ijd.15135. This article has 28 citations and is from a peer-reviewed journal.

  3. (vishnevskiadai2021naevusofota pages 1-2): Vicktoria Vishnevskia-Dai, Iris Moroz, Tal Davidy, Keren Zloto, Yael Birger, Ido Didi Fabian, Guy Ben Simon, Ayelet Priel, and Ofira Zloto. Naevus of ota: clinical characteristics and proposal for a new ocular classification and grading system. British Journal of Ophthalmology, 105:42-47, Mar 2021. URL: https://doi.org/10.1136/bjophthalmol-2019-313984, doi:10.1136/bjophthalmol-2019-313984. This article has 11 citations and is from a highest quality peer-reviewed journal.

  4. (zheng2024resultsandfollowup pages 1-2): Han Zheng, Ai-E Xu, Gang Qiao, Xiao-Yu Sun, Jia Deng, and Yong Zhang. Results and follow-up of a sequential q-switched laser therapy for nevus of ota in infants. Clinical, Cosmetic and Investigational Dermatology, 17:339-347, Feb 2024. URL: https://doi.org/10.2147/ccid.s444410, doi:10.2147/ccid.s444410. This article has 2 citations and is from a peer-reviewed journal.

  5. (vishnevskiadai2021naevusofota pages 1-1): Vicktoria Vishnevskia-Dai, Iris Moroz, Tal Davidy, Keren Zloto, Yael Birger, Ido Didi Fabian, Guy Ben Simon, Ayelet Priel, and Ofira Zloto. Naevus of ota: clinical characteristics and proposal for a new ocular classification and grading system. British Journal of Ophthalmology, 105:42-47, Mar 2021. URL: https://doi.org/10.1136/bjophthalmol-2019-313984, doi:10.1136/bjophthalmol-2019-313984. This article has 11 citations and is from a highest quality peer-reviewed journal.

  6. (zheng2024resultsandfollowup pages 4-6): Han Zheng, Ai-E Xu, Gang Qiao, Xiao-Yu Sun, Jia Deng, and Yong Zhang. Results and follow-up of a sequential q-switched laser therapy for nevus of ota in infants. Clinical, Cosmetic and Investigational Dermatology, 17:339-347, Feb 2024. URL: https://doi.org/10.2147/ccid.s444410, doi:10.2147/ccid.s444410. This article has 2 citations and is from a peer-reviewed journal.

  7. (NCT04481178 chunk 1): Woraphong Manuskiatti, M.D.. A Retrospective Study on Laser Treatment of Nevus of Ota in Thai Patients. Mahidol University. 2020. ClinicalTrials.gov Identifier: NCT04481178

  8. (toomey2019gnaqandpms1 pages 1-2): Christopher B. Toomey, Kyle Fraser, John A. Thorson, Michael H. Goldbaum, and Jonathan H. Lin. Gnaq and pms1 mutations associated with uveal melanoma, ocular surface melanosis, and nevus of ota. Ocular Oncology and Pathology, 5:267-272, Jan 2019. URL: https://doi.org/10.1159/000495508, doi:10.1159/000495508. This article has 11 citations and is from a peer-reviewed journal.

  9. (sharma2023intraoralnevusof pages 3-4): DR ARUN DEV SHARMA, DR AJAY PRATAP SINGH PARIHAR, DR PRASHANTHI REDDY, DR NIDHI YADAV, and DR RASHI MANDLIK. Intraoral nevus of ota : a case report and review. UNIVERSITY JOURNAL OF DENTAL SCIENCES, Jul 2023. URL: https://doi.org/10.21276/ujds.2023.9.3.19, doi:10.21276/ujds.2023.9.3.19. This article has 1 citations.

  10. (thomas2016mosaicactivatingmutations pages 2-3): Anna C. Thomas, Zhiqiang Zeng, Jean-Baptiste Rivière, Ryan O’Shaughnessy, Lara Al-Olabi, Judith St.-Onge, David J. Atherton, Hélène Aubert, Lorea Bagazgoitia, Sébastien Barbarot, Emmanuelle Bourrat, Christine Chiaverini, W. Kling Chong, Yannis Duffourd, Mary Glover, Leopold Groesser, Smail Hadj-Rabia, Henning Hamm, Rudolf Happle, Imran Mushtaq, Jean-Philippe Lacour, Regula Waelchli, Marion Wobser, Pierre Vabres, E. Elizabeth Patton, and Veronica A. Kinsler. Mosaic activating mutations in gna11 and gnaq are associated with phakomatosis pigmentovascularis and extensive dermal melanocytosis. The Journal of Investigative Dermatology, 136:770-778, Apr 2016. URL: https://doi.org/10.1016/j.jid.2015.11.027, doi:10.1016/j.jid.2015.11.027. This article has 234 citations.

  11. (thomas2016mosaicactivatingmutations pages 1-2): Anna C. Thomas, Zhiqiang Zeng, Jean-Baptiste Rivière, Ryan O’Shaughnessy, Lara Al-Olabi, Judith St.-Onge, David J. Atherton, Hélène Aubert, Lorea Bagazgoitia, Sébastien Barbarot, Emmanuelle Bourrat, Christine Chiaverini, W. Kling Chong, Yannis Duffourd, Mary Glover, Leopold Groesser, Smail Hadj-Rabia, Henning Hamm, Rudolf Happle, Imran Mushtaq, Jean-Philippe Lacour, Regula Waelchli, Marion Wobser, Pierre Vabres, E. Elizabeth Patton, and Veronica A. Kinsler. Mosaic activating mutations in gna11 and gnaq are associated with phakomatosis pigmentovascularis and extensive dermal melanocytosis. The Journal of Investigative Dermatology, 136:770-778, Apr 2016. URL: https://doi.org/10.1016/j.jid.2015.11.027, doi:10.1016/j.jid.2015.11.027. This article has 234 citations.

  12. (thomas2016mosaicactivatingmutations pages 3-5): Anna C. Thomas, Zhiqiang Zeng, Jean-Baptiste Rivière, Ryan O’Shaughnessy, Lara Al-Olabi, Judith St.-Onge, David J. Atherton, Hélène Aubert, Lorea Bagazgoitia, Sébastien Barbarot, Emmanuelle Bourrat, Christine Chiaverini, W. Kling Chong, Yannis Duffourd, Mary Glover, Leopold Groesser, Smail Hadj-Rabia, Henning Hamm, Rudolf Happle, Imran Mushtaq, Jean-Philippe Lacour, Regula Waelchli, Marion Wobser, Pierre Vabres, E. Elizabeth Patton, and Veronica A. Kinsler. Mosaic activating mutations in gna11 and gnaq are associated with phakomatosis pigmentovascularis and extensive dermal melanocytosis. The Journal of Investigative Dermatology, 136:770-778, Apr 2016. URL: https://doi.org/10.1016/j.jid.2015.11.027, doi:10.1016/j.jid.2015.11.027. This article has 234 citations.

  13. (pilch2024gnaqgna11relatedbenignand pages 6-7): Justyna Pilch, Jakub Mizera, Maciej Tota, and Piotr Donizy. Gnaq/gna11-related benign and malignant entities—a common histoembriologic origin or a tissue-dependent coincidence. Cancers, 16:3672, Oct 2024. URL: https://doi.org/10.3390/cancers16213672, doi:10.3390/cancers16213672. This article has 6 citations.

  14. (konstantinov2018nevusofota pages 3-3): NK Konstantinov, TM Berry, HR Elwood, and BJ Zlotoff. Nevus of ota associated with a primary uveal melanoma and intracranial melanoma metastasis. Unknown journal, 2018.

  15. (kumari2023bilateralnevusof pages 4-5): Pinki Kumari, Vartika, Pallavi UK, and Rajesh Sinha. Bilateral nevus of ota: a case series and literature review. Asian Journal of Medical Sciences, 14:326-331, Nov 2023. URL: https://doi.org/10.3126/ajms.v14i11.56108, doi:10.3126/ajms.v14i11.56108. This article has 0 citations.

  16. (seemongaldass2025acaseof pages 5-6): Rajiv V Seemongal-Dass, Robin R Seemongal-Dass, Alyssa P Singh, and Diego A Conocchiari. A case of nevus of ota in trinidad and tobago. Cureus, Jan 2025. URL: https://doi.org/10.7759/cureus.78311, doi:10.7759/cureus.78311. This article has 1 citations.

  17. (zheng2024resultsandfollowup media 94a4abe5): Han Zheng, Ai-E Xu, Gang Qiao, Xiao-Yu Sun, Jia Deng, and Yong Zhang. Results and follow-up of a sequential q-switched laser therapy for nevus of ota in infants. Clinical, Cosmetic and Investigational Dermatology, 17:339-347, Feb 2024. URL: https://doi.org/10.2147/ccid.s444410, doi:10.2147/ccid.s444410. This article has 2 citations and is from a peer-reviewed journal.

  18. (zheng2024resultsandfollowup media 9a87c0a6): Han Zheng, Ai-E Xu, Gang Qiao, Xiao-Yu Sun, Jia Deng, and Yong Zhang. Results and follow-up of a sequential q-switched laser therapy for nevus of ota in infants. Clinical, Cosmetic and Investigational Dermatology, 17:339-347, Feb 2024. URL: https://doi.org/10.2147/ccid.s444410, doi:10.2147/ccid.s444410. This article has 2 citations and is from a peer-reviewed journal.